Clinical program for NY-ESO-1 siTCR™ gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
Click here for the detail > News Release (2020/06/24)
Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV
Click here for the detail > News Release (2019/09/27)
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1 siTCR™ Gene Therapy at ESMO 2019
Click here for the detail > News Release (2019/09/24)
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1 siTCR™ Gene Therapy at ASCO 2019
Click here for the detail > News Release (2019/05/16)
Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan
Click here for the detail > News Release (2019/03/29)
Designation Description Change of NY-ESO-1 siTCR™ gene therapy product under "SAKIGAKE Designation System"
Click here for the detail > News Release (2019/02/15)
Takara to Present Oncolytic Virus C-REV Preliminary Data from the Phase I trial Targeting Unresectable Pancreatic Cancer at ASCO-GI 2019 Congress
Click here for the detail > News Release (2019/01/16)